Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Antiviral Therapy

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3851/IMP1506PMID 20386070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lopinavir/Ritonavir

  2012cited by this paper
• Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension

  2009cited by this paper
• HIV-related pulmonary arterial hypertension: clinical presentation and management

  2008cited by this paper
• Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay.

  2007cited by this paper
• Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects

  2007cited by this paper
• Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

  2007cited by this paper
• Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

  2007cited by this paper
• Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

  2007cited by this paper
• Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions

  2007cited by this paper
• Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

  2007cited by this paper
• HIV-related pulmonary hypertension.

  2006cited by this paper
• Pulmonary arterial hypertension in France: results from a national registry.

  2006cited by this paper
• DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP 1 B 1

  2006cited by this paper
• Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension

  2006cited by this paper
• DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1

  2006influential reference
• Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects

  2006cited by this paper
• [Guidelines on diagnosis and treatment of pulmonary arterial hypertension].

  2005cited by this paper
• The Plasma and Intracellular Steady-State Pharmacokinetics of Lopinavir/Ritonavir in HIV-1-Infected Patients

  2004cited by this paper
• Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.

  2004influential reference
• Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

  2004cited by this paper
• Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

  2004cited by this paper
• Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

  2003cited by this paper
• In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

  2002cited by this paper
• Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

  2002cited by this paper
• Evolving bioanalytical methods for the cardiovascular drug bosentan

  2002cited by this paper
• Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

  2001cited by this paper
• Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A.

  2000cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper

• Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)

  2022cites this paper
• Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)

  2022cites this paper
• Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications

  2020cites this paper
• Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

  2020cites this paper
• Role of transporters in drug disposition and drug-drug interactions

  2020cites this paper
• Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?

  2020influential citation
• SLC Family Transporters.

  2019cites this paper
• ABC Family Transporters.

  2019cites this paper
• The Discovery of Macitentan - A Standard Medicinal Chemistry Program?

  2017cites this paper
• HIV and Nonischemic Heart Disease.

  2017cites this paper
• THE COMPARISON OF THE STABILITY INDICATING TWO HPLC METHODS AND THEIR APPLICATION FOR THE DETERMINATION OF BOSENTAN IN COATED TABLETS.

  2016cites this paper
• Clinical drug-drug interactions of bosentan , a potent endothelial receptor antagonist , with various drugs : Physiological role of enzymes and transporters

  2016cites this paper
• Identification of Transporters Involved in Beraprost Sodium Transport In Vitro

  2016cites this paper
• Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters.

  2016cites this paper
• Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake.

  2016cites this paper
• Pharmacological treatment of HIV-associated pulmonary hypertension

  2016cites this paper
• Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites

  2016cites this paper
• Bosentan and Fosamprenavir: an effective and safe combination in an HIV-infected patient with pulmonary arterial hypertension

  2016cites this paper
• Response to a Dolutegravir-based Regimen in an HIV-Infected Woman with Multiple Comorbidities and a Highly Resistant Strain

  2015cites this paper
• Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension

  2015cites this paper
• Current Treatment Strategies, Guidelines and New Therapies

  2015cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Sildenafil and Bosentan Plasma Concentrations in a Human Immunodeficiency Virus- Infected Patient with Pulmonary Arterial Hypertension Treated with Ritonavir-Boosted Protease Inhibitor

  2015cites this paper
• Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.

  2014cites this paper
• Macitentan Does Not Interfere with Hepatic Bile Salt Transport

  2014influential citation
• Hipertensión pulmonar asociada a HIV

  2014cites this paper
• Biomarkers and human hepatocytes.

  2014cites this paper
• In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery

  2014cites this paper
• In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.

  2014cites this paper
• Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.

  2013cites this paper
• Association of CYP2C9*2 With Bosentan‐Induced Liver Injury

  2013cites this paper
• Organic anion-transporting polypeptides (OATPs/SLCOs)

  2013cites this paper
• Enzyme and transporter-mediated drug-drug and herb-drug interactions of the antimalarials and HIV antiretrovirals

  2013cites this paper
• Inhibiteurs des récepteurs plaquettaires P2Y12 à l'ADP: importance du métabolisme et influence des interactions médicamenteuses sur leurs paramètres pharmacocinétiques

  2012cites this paper
• In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation

  2012cites this paper
• Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs

  2012cites this paper
• Safety and efficacy evaluation of ambrisentan in pulmonary hypertension

  2012cites this paper
• Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

  2012cites this paper
• The Pharmacological Treatment of Pulmonary Arterial Hypertension

  2012cites this paper
• Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future.

  2011cites this paper
• Mechanisms of Drug Interactions II: Transport Proteins

  2011cites this paper
• Clinical Importance of OATP 1 B 1 and OATP 1 B 3 in Drug Drug Interactions

  2011cites this paper
• Bosentan for the treatment of adult pulmonary hypertension.

  2011cites this paper
• Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far

  2011cites this paper
• Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.

  2011cites this paper